)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
GlycoMimetics (GLYC) investor relations material
GlycoMimetics Q1 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2025 earnings summary13 May, 2025
Executive summary
GlycoMimetics ceased development of its drug candidates after negative Phase 3 and Phase 2 trial results for uproleselan in AML, with no statistically significant benefit observed and no ongoing clinical trials as of March 31, 2025.
The company initiated a strategic review, reduced its workforce by 80%, and entered into a merger agreement with Crescent Biopharma, expected to close in Q2 2025, after which Crescent's business will become primary.
A $200 million private placement is planned to close concurrently with the merger, with pre-merger GlycoMimetics shareholders expected to own only 2.6% of the combined company post-transaction.
Financial highlights
Net loss for Q1 2025 was $2.34 million, a significant improvement from a $10.74 million net loss in Q1 2024, reflecting the wind-down of operations.
Research and development expenses dropped to $15,000 in Q1 2025 from $6.03 million in Q1 2024; general and administrative expenses fell to $2.38 million from $5.09 million year-over-year.
Cash and cash equivalents were $5.6 million as of March 31, 2025, down from $10.7 million at year-end 2024.
Net cash used in operating activities was $5.1 million in Q1 2025, down from $10.5 million in Q1 2024.
No revenue was recognized in Q1 2025; the Apollomics license agreement was terminated effective May 21, 2025.
Outlook and guidance
Current cash is expected to fund operations until the merger closes; if the merger and private placement do not close by Q3 2025, the company may seek other alternatives or liquidate.
No plans to continue development of uproleselan or other drug candidates; Crescent Biopharma's pipeline will become the focus post-merger.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
GlycoMimetics Inc. is a clinical-stage biotechnology company focused on developing novel therapies that target the role of sugars in disease, particularly in the areas of cancer and inflammatory diseases. The company’s drug candidates are designed to block specific carbohydrate interactions that contribute to disease progression, with a focus on improving treatment outcomes for patients with blood cancers and rare diseases. GlycoMimetics develops small-molecule glycomimetic compounds that are intended to disrupt key biological processes in various disease states. The company is headquartered in Rockville, Maryland, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage